{"pub": "reuters", "url": "https://in.reuters.com/article/bangladesh-ranitidine/bangladesh-bans-heartburn-drug-ranitidine-over-cancer-fears-idINKBN1WE0IR", "downloaded_at": "2019-09-29 23:35:51.651649+00:00", "title": "Bangladesh bans heartburn drug ranitidine over cancer fears", "language": "en", "text": "DHAKA (Reuters) - Bangladesh\u2019s drug regulatory authority on Sunday issued a ban on sales of popular heartburn drug ranitidine while it investigates a potential cancer-causing substance in the drug.\n\nThe move comes after the U.S. Food and Drug Administration (FDA) warned that some of the pills contained small amounts N-nitrosodimethylamine (NDMA), which the regulator says is a \u201cprobable human carcinogen\u201d.\n\n\u201cWe have banned the import of raw materials, production and sale of ranitidine until further notice,\u201d said Khandaker Sagir Ahmed, a director of Bangladesh\u2019s drug regulatory authority, adding that the decision was taken a precautionary measure.\n\nDrug manufacturers across the world have begun recalling the widely taken heartburn drug, which is sold under the trade name Zantac among others, while the FDA and European drug regulators review whether low levels of NDMA in ranitidine pose a health risk to patients.\n\nDomestic companies affected include Beximco Pharmaceuticals and Square Pharmaceuticals, which produce ranitidine under the Neoceptin R and Neotack brands respectively.\n\nThe Bangladesh drug regulatory authority will test drug samples but has also asked domestic manufacturers to test their drugs in accredited labs and send reports to the watchdog, Ahmed said.", "description": "Bangladesh's drug regulatory authority on Sunday issued a ban on sales of popular heartburn drug ranitidine while it investigates a potential cancer-causing substance in the drug.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "published_at": "2019-09-29"}